Oral sitafloxacin vs intravenous ceftriaxone followed by oral cefdinir for acute pyelonephritis and complicated urinary tract infection: a randomized controlled trial.

Background: The conventional antibiotic regimen for community-acquired upper urinary tract infections with moderate severity in Thailand is parenteral ceftriaxone (CTRX) for several days followed by oral cephalosporin for 7-14 days. The aim of this study was to compare the efficacy and safety of oral sitafloxacin (STFX) with that of intravenous CTRX followed by oral cefdinir (CFDN) for the therapy of acute pyelonephritis (APN) and complicated urinary tract infection (cUTI).

Methods: This open-label, randomized, controlled, noninferiority clinical trial included patients from nine centers across Thailand.

Chronic diarrhoea caused by Cryptococcus neoformans in a non-human immunodeficiency virus-infected patient.

A 43-y-old woman with underlying cervix carcinoma stage IIIB, status postirradiation, and diabetes mellitus with tripathy suffered from chronic diarrhoea for more than 6 months. Stool examination showed few white blood cells and red blood cells. Rectal swab cultures disclosed Cryptococcus neoformans in 2 samples obtained 2 weeks apart.

An open, non comparative study of ofloxacin i.v. on the treatment of acute symptomatic urinary tract infection.

The clinical efficacy and the safety of ofloxacin i.v. in 35 acute symptomatic urinary tract patients were evaluated.

Antifungal drug combinations for Cryptococcus neoformans and Prototheca spp.

Seventy-one isolates of Cryptococcus neoformans and 5 isolates of Prototheca spp. were tested for in vitro susceptibility against amphotericin B alone and against the combination of amphotericin B with each clinically relevant concentration of flucytosine (5-FC) and rifampin by broth dilution methods. The combinations of amphotericin B and rifampin produced greater effect on reduction of the minimal inhibition concentration (MIC) of amphotericin B than did either drug used individually.

In vitro activity and clinical evaluation of cefixime in urinary tract infection.

Thirty-five women with uncomplicated acute lower urinary tract infections proven by significant pre-treatment bacteriuria (> or = 10(5)CFU/ml) were treated with an oral dose of 100 mg cefixime twice a day for seven days. Thirty five patients included in this study were checked for response to treatment on the last day of therapy, 7-14 days and 4 weeks post therapy. The clinical response and bacterial eradication rate for cefixime were 91.